RESUMO
Massive present-day early-type (elliptical and lenticular) galaxies probably gained the bulk of their stellar mass and heavy elements through intense, dust-enshrouded starbursts--that is, increased rates of star formation--in the most massive dark-matter haloes at early epochs. However, it remains unknown how soon after the Big Bang massive starburst progenitors exist. The measured redshift (z) distribution of dusty, massive starbursts has long been suspected to be biased low in z owing to selection effects, as confirmed by recent findings of systems with redshifts as high as ~5 (refs 2-4). Here we report the identification of a massive starburst galaxy at z = 6.34 through a submillimetre colour-selection technique. We unambiguously determined the redshift from a suite of molecular and atomic fine-structure cooling lines. These measurements reveal a hundred billion solar masses of highly excited, chemically evolved interstellar medium in this galaxy, which constitutes at least 40 per cent of the baryonic mass. A 'maximum starburst' converts the gas into stars at a rate more than 2,000 times that of the Milky Way, a rate among the highest observed at any epoch. Despite the overall downturn in cosmic star formation towards the highest redshifts, it seems that environments mature enough to form the most massive, intense starbursts existed at least as early as 880 million years after the Big Bang.
RESUMO
6-Azaandrost-4-en-3-ones were synthesized and tested versus human type 1 and 2 steroid 5 alpha-reductase (5AR) and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase (3BHSD) to explore the structure-activity relationship of this novel series in order to optimize potency versus both isozymes of 5AR and selectivity versus 3BHSD. Compounds with picomolar IC50's versus human type 2 5AR and low nanomolar Ki's versus human type 1 5AR with 100-fold selectivity versus 3BHSD were identified (70). Preliminary in vivo evaluation of some optimal compounds from this series in a chronic castrated rat model of 5AR inhibitor-induced prostate involution and dog pharmacokinetic measurements identified a series of 17 beta-[N-(diphenylmethyl)carbamoyl]-6-azaandrost-4-en-3-ones (compounds 54, 66, and 67) with good in vivo efficacy and half-life in the dog. Inhibitors with, at the minimum, low nanomolar potency toward both human 5AR's and selectivity versus 3BHSD may show advantages over previously known 5AR inhibitors in the treatment of disease states which depend upon dihydrotestosterone, such as benign prostatic hyperplasia.
Assuntos
3-Hidroxiesteroide Desidrogenases/antagonistas & inibidores , Inibidores de 5-alfa Redutase , Glândulas Suprarrenais/enzimologia , Azasteroides/farmacologia , Isoenzimas/antagonistas & inibidores , Esteroide Isomerases/antagonistas & inibidores , Animais , Azasteroides/química , Cães , Humanos , Ratos , Ratos Sprague-Dawley , Relação Estrutura-AtividadeRESUMO
A variety of C17 amide-substituted 6-azaandrost-4-en-3-ones were prepared and tested versus human type 1 and 2 steroid 5 alpha-reductase (5AR) and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase (3BHSD) in order to optimize potency versus both isozymes of 5AR and selectivity versus 3BHSD. Two series of potent and selective C17 amides were discovered, 2,5-disubstituted anilides and (arylcycloalkyl)amides. Compounds from each series with picomolar IC50's versus human type 2 5AR and low nanomolar to picomolar IC50's versus human type 1 5AR possessing 100-500-fold selectivity versus 3BHSD were identified. A conformational model to predict 3BHSD potency was developed which could rationalize 3BHSD potency within three different series of compounds. Evaluation of some optimal compounds from this series in a chronic castrated rat model of 5AR inhibitor induced prostate involution, and pharmacokinetic measurements identified compounds (9, 12, 16, and 29) with good in vivo efficacy and half-life in the dog. An intact rat model of in vivo selectivity for 5AR versus 3BHSD inhibition was also developed. Dual inhibitors of both human 5AR's may show advantages over type 2 selective 5AR inhibitors, such as finasteride (1), in the treatment of disease states which depend upon dihydrotestosterone.
Assuntos
3-Hidroxiesteroide Desidrogenases/antagonistas & inibidores , Inibidores de 5-alfa Redutase , Glândulas Suprarrenais/enzimologia , Azasteroides/farmacologia , Esteroide Isomerases/antagonistas & inibidores , Animais , Azasteroides/química , Azasteroides/farmacocinética , Cães , Humanos , Masculino , Modelos Moleculares , Ratos , Ratos Sprague-Dawley , Relação Estrutura-AtividadeRESUMO
A series of substituted phenethyl derivatives of 3-benzisothiazolylpiperazine incorporating potent D2 and 5-HT2A antagonist activity was investigated as an approach to a novel atypical antipsychotic agent. The in vitro profile of 8e from this series is a combination of D2 receptor affinity comparable to the typical antipsychotic agent haloperidol and a 5-HT2A/D2 ratio comparable to the atypical agent clozapine. In vivo 8e possesses activity consistent with an efficacious antipsychotic agent with less tendency to induce extrapyramidal side effects in man.
Assuntos
Antipsicóticos/farmacologia , Piperazinas/farmacologia , Antagonistas da Serotonina/farmacologia , Tiazóis/farmacologia , Anfetamina/farmacologia , Animais , Antipsicóticos/química , Apomorfina/farmacologia , Aprendizagem da Esquiva/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Catalepsia/metabolismo , Clozapina/farmacologia , Dopamina/metabolismo , Dopamina/farmacologia , Desenho de Fármacos , Humanos , Estrutura Molecular , Fosfatidilinositóis/antagonistas & inibidores , Fosfatidilinositóis/metabolismo , Piperazinas/química , Prazosina/antagonistas & inibidores , Prazosina/metabolismo , Ratos , Receptores Adrenérgicos/metabolismo , Receptores Dopaminérgicos/metabolismo , Antagonistas da Serotonina/química , Tiazóis/químicaAssuntos
Proteínas de Ligação a DNA/agonistas , Isoxazóis/síntese química , Receptores Citoplasmáticos e Nucleares/agonistas , Fatores de Transcrição/agonistas , Animais , Disponibilidade Biológica , Linhagem Celular , Sistema Livre de Células , Técnicas de Química Combinatória , Humanos , Isoxazóis/química , Isoxazóis/farmacocinética , Isoxazóis/farmacologia , Camundongos , Ratos , Ratos Endogâmicos F344 , Transfecção , Triglicerídeos/sangueAssuntos
Inibidores de 5-alfa Redutase , Azasteroides/síntese química , Isoenzimas/antagonistas & inibidores , Animais , Azasteroides/farmacologia , Baculoviridae/genética , Linhagem Celular , Di-Hidrotestosterona/metabolismo , Humanos , Masculino , Mariposas , Orquiectomia , Ratos , Ratos Sprague-Dawley , Proteínas Recombinantes/antagonistas & inibidores , Testosterona/metabolismo , TransfecçãoRESUMO
Bile acids repress the transcription of cytochrome P450 7A1 (CYP7A1), which catalyzes the rate-limiting step in bile acid biosynthesis. Although bile acids activate the farnesoid X receptor (FXR), the mechanism underlying bile acid-mediated repression of CYP7A1 remained unclear. We have used a potent, nonsteroidal FXR ligand to show that FXR induces expression of small heterodimer partner 1 (SHP-1), an atypical member of the nuclear receptor family that lacks a DNA-binding domain. SHP-1 represses expression of CYP7A1 by inhibiting the activity of liver receptor homolog 1 (LRH-1), an orphan nuclear receptor that is known to regulate CYP7A1 expression positively. This bile acid-activated regulatory cascade provides a molecular basis for the coordinate suppression of CYP7A1 and other genes involved in bile acid biosynthesis.